If diabetes were a stock, it'd be booming: the CDC says that the number of people with diagnosed diabetes has increased by 373% over the past 30 years, from 5.6 million in 1980 to 20.9 million in 2011. What new medicines are coming out to help turn diabetes' boom into a bust?
You've seen GEN's list of 15 breast cancer drugs that are currently in the pipeline; now, GEN has compiled a list of 25 drug candidates for which diabetes is at least one proposed or approved indication, and for which one indication has reached Phase III or Registration phases. Each entry includes the name of the drug candidate, the sponsor, and, where applicable, collaboration partners; method of action; indication (by market, where applicable); and phase of trial. Some products are still in clinical trial phases for new indications or formulations after winning marketing approval for initial indications; these approvals, where applicable, are listed on the bottom of each entry.